Thetis Builds SAB to Guide Development of Immuno-Resolving Therapies for IBD

Stephen Hanauer, MD, Joshua Korzenik, MD, and Florian Rieder, MD join the board BRANFORD, CT – (GlobeNewswire – December 11, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel disease (IBD), announced that Stephen Hanauer, MD, Josh Korzenik, MD, and Florian Rieder, MD, have joined Thetis’ Scientific […]

Senator Murphy Names Thetis Connecticut Innovator of the Month

WASHINGTON – In recognition of Crohn’s and Colitis Awareness Week, U.S. Senator Chris Murphy (D-Conn.) announced on Tuesday that Branford’s Thetis Pharmaceuticals – a biopharmaceutical company developing new oral therapies to treat inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis – is this month’s “Murphy’s Innovator of the Month.” Thetis has a proprietary HEALER™ […]

Thetis Receives $2.3 Million NIH Grant to Develop Immuno-Resolving Therapy for IBD

  Resolvin-based agent targets inflammation resolution and tissue regeneration without immunosuppression BRANFORD, CT – (GlobeNewswire – November 16, 2017) – Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). […]

Thetis Announces Pre-Clinical Data on TP-252

Preclinical data shows equivalence of TP-252 and EPA-FFA in modulating inflammatory eicosanoid profiles within the colon EPA-FFA has demonstrated clinical efficacy in reducing the rate of relapse in ulcerative colitis BRANFORD, CT May 8, 2017 – Thetis Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs for inflammatory bowel disease (IBD), today announced pre-clinical data […]

Thetis Announces Immuno-Resolving Therapies for Inflammatory Bowel Disease

– Lead candidate TP-252 expected to begin clinical studies in 2018 BRANFORD, CT– (May 5, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing small molecule drugs for treatment of gastrointestinal diseases, announced two development candidates, TP-252 and TP-317, for treatment of inflammatory bowel disease (IBD). Gary Mathias, co-founder and chief executive officer, commented, […]